A Study to Investigate Drug Interaction Between D326, D337, and D013 in Healthy Male Subjects

• Status: Completed
• Trial end date: 2018-09-27
• Target enrollment: 0
• Participant gender: Male

Summary

A study to investigate drug interaction between D326, D337, and D013 in healthy male subjects

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Chong Kun Dang Pharmaceutical

Criteria

Inclusion Criteria:

1. Healthy volunteers aged between ≥ 20 and ≤ 45 years old

2. Weight ≥ 50kg, with calculated body mass index(BMI) of ≥ 18 and ≤ 29.9kg/m²

3. Subjects who agree to use a combination of effective contraceptive methods or medically acceptable contraceptive methods for up to 28 days after the date of administration of the clinical trial drug and agree not to provide sperm

4. Subject who are informed of the investigational nature of this study, voluntarily agree to participate in this study

Exclusion Criteria:

1. History or presence of clinically significant and active cardiovascular, respiratory, hepatobiliary, renal, hematological, gastrointestinal, endocrine, immune, dermatologic, neurologic or psychiatric disorder

2. With symptoms indicating acute illness within 28 days prior to the first Investigational Product administration

3. Any medical history that may affect drug absorption, distribution, metabolism and excretion

4. Genetic problems such as galactose intolerance, Lapp lactose dehydrogenase deficiency or glucose-galactose uptake disorder

5. Any clinically significant active chronic disease